Galmed Pharmaceuticals (GLMD) – Investment Analysts’ Recent Ratings Updates

Galmed Pharmaceuticals (NASDAQ: GLMD) has recently received a number of price target changes and ratings updates:

  • 11/13/2018 – Galmed Pharmaceuticals was given a new $20.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 11/8/2018 – Galmed Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
  • 11/6/2018 – Galmed Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 11/5/2018 – Galmed Pharmaceuticals was given a new $59.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/27/2018 – Galmed Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 10/16/2018 – Galmed Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
  • 10/10/2018 – Galmed Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
  • 10/2/2018 – Galmed Pharmaceuticals was given a new $59.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

GLMD traded down $0.26 on Monday, reaching $8.51. The company had a trading volume of 2,834 shares, compared to its average volume of 159,073. Galmed Pharmaceuticals Ltd has a 1 year low of $3.61 and a 1 year high of $27.06. The stock has a market cap of $139.51 million, a PE ratio of -8.68 and a beta of 2.90.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.09. Galmed Pharmaceuticals had a negative net margin of 423.62% and a negative return on equity of 18.55%. The firm had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, analysts anticipate that Galmed Pharmaceuticals Ltd will post -0.52 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Crawford Lake Capital Management LLC bought a new stake in shares of Galmed Pharmaceuticals in the 2nd quarter worth about $158,000. UBS Group AG lifted its position in Galmed Pharmaceuticals by 5,334.8% during the 1st quarter. UBS Group AG now owns 40,000 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 39,264 shares in the last quarter. Trellus Management Company LLC acquired a new position in Galmed Pharmaceuticals during the 3rd quarter worth about $227,000. First Midwest Bank Trust Division acquired a new position in Galmed Pharmaceuticals during the 2nd quarter worth about $282,000. Finally, Jane Street Group LLC acquired a new position in Galmed Pharmaceuticals during the 2nd quarter worth about $284,000. 55.11% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Read More: What are no-load funds?

Receive News & Ratings for Galmed Pharmaceuticals Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply